N. C. Tebbutt

816 total citations
17 papers, 173 citations indexed

About

N. C. Tebbutt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, N. C. Tebbutt has authored 17 papers receiving a total of 173 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in N. C. Tebbutt's work include Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Gastric Cancer Management and Outcomes (4 papers). N. C. Tebbutt is often cited by papers focused on Colorectal Cancer Treatments and Studies (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Gastric Cancer Management and Outcomes (4 papers). N. C. Tebbutt collaborates with scholars based in Australia, Canada and New Zealand. N. C. Tebbutt's co-authors include Rebecca Herbertson, Andrew M. Scott, Andrew Scarsbrook, W. Ivon Burns, R. Snyder, Michelle M. Cummins, Vinod Ganju, A. H. Strickland, Val Gebski and T. Sourjina and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

N. C. Tebbutt

16 papers receiving 169 citations

Peers

N. C. Tebbutt

ONCOL

PRM

RNMI

SURGE

Satoshi Shinya Japan

Irene Pecora Italy

Wafaa Elatre United States

Vincenzo Panebianco Italy

Nick Pavlakis Australia

Cristina Morelli Italy

Tomokazu Hisayuki Japan

Brittanie M Millang United States

Fabiana Vitiello Italy

Satoshi Shinya Japan

N. C. Tebbutt

84 ×0.7

ONCOL

82 ×1.2

PRM

89 ×2.1

RNMI

102 ×3.2

SURGE

35 ×1.3

Citations per year, relative to N. C. Tebbutt N. C. Tebbutt (= 1×) peers Satoshi Shinya

Countries citing papers authored by N. C. Tebbutt

Since Specialization

Citations

This map shows the geographic impact of N. C. Tebbutt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. C. Tebbutt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. C. Tebbutt more than expected).

Fields of papers citing papers by N. C. Tebbutt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. C. Tebbutt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. C. Tebbutt. The network helps show where N. C. Tebbutt may publish in the future.

Co-authorship network of co-authors of N. C. Tebbutt

This figure shows the co-authorship network connecting the top 25 collaborators of N. C. Tebbutt. A scholar is included among the top collaborators of N. C. Tebbutt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. C. Tebbutt. N. C. Tebbutt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

O’Callaghan, Christopher, Christos S. Karapetis, Timothy Price, et al.. (2018). Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response. Current Oncology. 25(6). 516–526. 13 indexed citations

Gracián, Antonio Cubillo, Andrew Dean, Andrés Muñoz, et al.. (2017). YOSEMITE: A 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD). Annals of Oncology. 28. v211–v211. 22 indexed citations

Diakos, Connie I., Val Gebski, Sidney Kam‐Hung Yip, et al.. (2016). Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies. Annals of Oncology. 27. vi196–vi196. 2 indexed citations

Shinozaki, Eiji, Stéphanie Laurent, Cristina Grávalos, et al.. (2015). 2151 Timing of adverse events (AEs) in the Phase 3 RECOURSE trial of TAS-102 versus placebo in patients (pts) with metastatic colorectal cancer (mCRC). European Journal of Cancer. 51. S383–S384. 5 indexed citations

Zalcberg, John, Peter Gibbs, Lara Lipton, et al.. (2012). A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 71(2). 321–330. 8 indexed citations

Tebbutt, N. C., Lara Lipton, Ralph V. Boccia, et al.. (2011). The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). e13555–e13555. 3 indexed citations

Schofield, Philip, Martin R. Stockler, Diana Zannino, et al.. (2010). Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 28(15_suppl). 9039–9039. 1 indexed citations

Azad, Arun, et al.. (2009). 18F-FDG-PET imaging of a benign neurofibroma masquerading as metastatic oesophageal carcinoma. Medical Oncology. 27(2). 230–232. 1 indexed citations

Herbertson, Rebecca, et al.. (2008). Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clinical Radiology. 64(3). 225–237. 44 indexed citations

10.

Scott, Andrew M., Rebecca Herbertson, Bridget Chappell, et al.. (2008). Phase I biodistribution study of Le^y targeting immunoconjugate in advanced epithelial cancers. Journal of Clinical Oncology. 26(15_suppl). 3025–3025. 1 indexed citations

11.

Kotasek, Dusan, et al.. (2008). Safety and pharmacokinetics (PK) of motesanib diphosphate in combination with gemcitabine (G) and erlotinib (E) for the treatment of patients (pts) with solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3560–3560. 1 indexed citations

12.

Tebbutt, N. C., T. Sourjina, A. H. Strickland, et al.. (2008). ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer—Final results of a multicentre phase II trial by the AGITG. Journal of Clinical Oncology. 26(15_suppl). 15554–15554. 22 indexed citations

13.

Stockler, Martin R., Timothy Price, Guy A. Van Hazel, et al.. (2008). Comparing utilities for advanced colorectal cancer valued from societal and cancer patients' perspectives using baseline data from the MAX study. Journal of Clinical Oncology. 26(15_suppl). 6504–6504. 2 indexed citations

14.

Herbertson, Rebecca, et al.. (2007). The expanding role of PET technology in the management of patients with colorectal cancer. Annals of Oncology. 18(11). 1774–1781. 20 indexed citations

15.

Tebbutt, N. C., T. Sourjina, A. H. Strickland, et al.. (2007). ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago- gastric cancer, final results of an AGITG trial. Journal of Clinical Oncology. 25(18_suppl). 4528–4528. 12 indexed citations

16.

Chau, Ian, Mark Allen, David Cunningham, et al.. (2003). 51 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer: analysis from a prospective randomised controlled trial. European Journal of Cancer Supplements. 1(5). S20–S20.

17.

Tebbutt, N. C., R. Snyder, & W. Ivon Burns. (1997). An analysis of the outcomes of treatment of small cell lung cancer in the elderly. Australian and New Zealand Journal of Medicine. 27(2). 160–164. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact